Institutional & Family Asset Management’s SAB Biotherapeutics SABS Stock Holding History

Institutional & Family Asset Management’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$59.5K	Hold	19,201	–	–	0.01%	223
2024 Q1	$87.2K	Sell	19,201 -2	-0%	-$11	0.01%	198
2023 Q4	$132K	Hold	19,203	–	–	0.02%	159
2023 Q3	$121K	Hold	19,203	–	–	0.02%	162
2023 Q2	$159K	Buy	19,203 +4,226	+28%	+$34.6K	0.03%	154
2023 Q1	$65.9K	Hold	14,977	–	–	0.01%	202
2022 Q4	$88.4K	Hold	14,977	–	–	0.01%	178
2022 Q3	$105K	Buy	14,977 +7,165	+92%	+$71.1K	0.02%	166
2022 Q2	$113K	Hold	7,812	–	–	0.02%	164
2022 Q1	$294K	Hold	7,812	–	–	0.05%	131
2021 Q4	$610K	Buy	7,812 +7,312	+1,462%	+$686K	0.1%	112
2021 Q3	$50K	Buy	+500	New	+$49.9K	0.01%	324

Other funds holding SABS

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

FPB

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

Institutional & Family Asset Management's SABS Position: Q2 2024 in Review

Institutional & Family Asset Management held its SAB Biotherapeutics (SABS) position steady in Q2 2024 at 19,201 shares worth $59.5K. The position accounts for 0.01% of the portfolio, ranked #223.

Institutional & Family Asset Management first reported a position in SABS in Q3 2021 and has held it in 12 quarters since. The position peaked at $610K in Q4 2021. 22 funds tracked by Wall St. Rank hold SABS as of Q2 2024.

Institutional & Family Asset Management held 19,201 shares of SAB Biotherapeutics worth $59.5K as of Q2 2024.
Institutional & Family Asset Management left its SAB Biotherapeutics share count unchanged in Q2 2024.
SAB Biotherapeutics made up 0.01% of Institutional & Family Asset Management's portfolio in Q2 2024, its #223 holding.
Institutional & Family Asset Management first reported a position in SAB Biotherapeutics in Q3 2021 and has held it in 12 quarters since.
Institutional & Family Asset Management's SAB Biotherapeutics position peaked at $610K in Q4 2021.
22 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2024.

Based on Institutional & Family Asset Management's 13F filing for Q2 2024, filed 5 Jul 2024.